2023
Radiotherapy Utilization and Outcomes on a Contemporary Trial for Pediatric High-Risk Hodgkin Lymphoma Study
Hoppe B, Castellino S, Pei Q, Charpentier A, Keller F, Vega R, Roberts K, Parikh R, Punnett A, Parsons S, McCarten K, Flampouri S, Kessel S, Wu Y, Cho S, Kelly K, Hodgson D. Radiotherapy Utilization and Outcomes on a Contemporary Trial for Pediatric High-Risk Hodgkin Lymphoma Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s62-s63. DOI: 10.1016/j.ijrobp.2023.06.362.Peer-Reviewed Original ResearchProgression-free survivalBrentuximab vedotinABVE-PCIrradiated patientsMediastinal adenopathyRadiotherapy utilizationContemporary trialsRT modalityOpen-label phase 3 studyExcellent progression-free survivalUse of PTProgression-free survival ratesProton therapyHodgkin's lymphoma studyUtilization of RTSevere acute toxicityPhase 3 studyPediatric Hodgkin lymphomaSimilar acute toxicityAcute toxicityMATERIAL/METHODSDifferent RT modalitiesEligible patientsMedian followPediatric patients
2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group
Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 890-900. PMID: 34767937, PMCID: PMC9038118, DOI: 10.1016/j.ijrobp.2021.10.152.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapySlow early responseClassical Hodgkin lymphomaBulky diseaseOncology GroupHodgkin's lymphomaRetrospective analysisChildren's Oncology Group protocolsHigh-risk Hodgkin lymphomaRadiation treatment volumesCycles of doxorubicinHigh-risk patientsPhase 3 studyTime of progressionChildren's Oncology GroupPatterns of failureInitial siteABVE-PCConsolidation RTEligible patientsField relapseInitial relapseMedian followRelapse siteStage IIIB